The global rise in anticoagulant use has increased the number of major bleeding events that warrant timely and effective pharmacologic reversal. Reversal strategies should be informed by the ...
Upcoming US approval decisions in the third quarter of 2026 include centanafadine for attention deficit hyperactivity disorder (ADHD), 177 Lu-edotreotide for gastroenteropancreatic neuroendocrine ...
What Is It, and Why Does It Matter? Truqap (capivasertib) is an oral targeted cancer medicine. The FDA has now approved it to be used together with abiraterone and prednisone for a specific type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results